Healthcare AI Monitoring Plan: What to Review in the First 90 Days After Go-Live

Author: Eunoia Consulting Co. | Published: October 1, 2026

A practical healthcare AI monitoring plan for the first 90 days after go-live: select context-specific signals, capture feedback, manage changes, set escalation paths and retain decision-ready evidence.

Healthcare organisations do not need to treat every AI-enabled workflow as if it requires the same monitoring dashboard, meeting schedule, or escalation threshold. They do need a clear way to notice when the defined use, data, workflow, outcomes, or risk assumptions have changed after launch.

A healthcare AI monitoring plan is that operating agreement. It records what the organisation will observe, who reviews it, how staff and affected users can report concerns, what triggers an escalation, and how a system can be paused, bypassed, changed, or retired when its outcomes are inconsistent with its intended use.

This article offers a practical 90-day starting structure for healthcare operators. It draws on the voluntary NIST AI Risk Management Framework and its Measure and Manage guidance. It is not a universal control set, clinical standard, legal advice, compliance certification, or guarantee that an AI system is safe, fair, effective, secure, or appropriate for a particular organisation.

Start with the use that was actually approved

Monitoring becomes unfocused when a team begins with a generic list of metrics instead of the specific workflow that was approved. Before go-live, write a concise use statement that names:

• the intended user and the workflow step;
• the output the system produces and the action it may influence;
• the human review, override, or escalation point;
• the relevant population, site, service line, or operating context;
• out-of-scope uses; and
• the facts that would require the use statement to be reconsidered.

That statement becomes the reference point for post-launch review. A change in the data feed, model or feature version, workflow integration, user group, decision role, or local operating setting can matter even if a vendor release note calls the change minor.

NIST’s AI RMF describes risk management as continuous and lifecycle-based. Its Measure function calls for approaches and metrics selected from the material risks identified for the use context—not a one-size-fits-all checklist. The framework also recognises that some characteristics may not be measurable with available methods; those limits should be documented rather than hidden.

> Eunoia recommendation: Treat the approved intended-use statement as a controlled operating record. Any material departure should return to a named owner for review before the new use becomes routine.

Choose a small set of signals that answer decision questions

A useful plan asks, “What decision will this signal help us make?” before it asks, “What can the platform measure?” A team may need different signals for a workflow-support tool, predictive intervention, documentation assistant, scheduling workflow, or revenue-operations capability.

For each selected signal, record the definition, source, collection method, owner, review cadence, intended interpretation, known limitation, and action if the signal crosses a defined threshold. Avoid treating a single rate, score, or dashboard as a conclusion by itself.

Four signal groups often make the discussion more practical:

1. Intended-use fit and human oversight

Review whether people are using the system in the approved workflow and whether the designated human role is working in practice. Depending on the use case, relevant evidence might include training completion, documented overrides, reasons for non-use, exception patterns, and feedback about whether the output is understandable enough to evaluate.

NIST’s Measure guidance suggests documenting the degree of oversight provided by specified AI actors and maintaining information about downstream actions such as overrides. That does not mean every workflow needs the same override metric. It means the organisation should be able to explain the human responsibility it designed and how it knows that responsibility remains usable.

2. Inputs, context and operating changes

Monitor the parts of the environment that can change the meaning of an output: source data, integrations, access roles, configuration, vendor-supplied components, population, care setting, or workflow routing. A stable-looking output is not proof that the surrounding assumptions remain stable.

A concise change record should note what changed, when, who assessed it, which use statement or evidence item it affected, and whether it can proceed, requires conditions, or needs escalation. Healthcare AI vendor change control is a practical companion to this monitoring discipline.

3. Outcome, reliability and risk signals

Use metrics that are fit for the specific task and decision consequence. The appropriate approach may involve accuracy or error-pattern analysis, turnaround time, workflow completion, reconciliation exceptions, model or service availability, reliability of an integration, differences between intended and actual use, or comparison with a defined non-AI baseline.

NIST’s Measure playbook recommends establishing approaches to detect, track, and measure known risks, errors, incidents, or negative impacts; documenting acceptable limits; and assessing pre- and post-deployment performance. It also recommends documenting the risks or characteristics that will not be measured and why. That is valuable because it prevents a monitoring plan from implying more certainty than the organisation has.

4. Feedback, exceptions and incidents

Users, support teams, operations leaders, and people affected by an AI-enabled workflow may see problems before a reporting metric does. Give them a clear route to raise a concern, attach the relevant evidence, and learn what happens next.

A practical issue record can capture the date, system or workflow, description, reporter role, immediate containment action, severity or prioritisation rationale, accountable owner, investigation status, decision, response, communication need, and closure evidence. NIST identifies feedback processes, error-response tracking, and documented response and recovery as elements of responsible AI risk management.

Use the first 90 days to test the monitoring plan itself

The first 90 days should not be presented as a regulatory timetable. It is an operating pattern organisations can adapt to their risk, maturity, contracts, and clinical or business context.

Days 0–30: confirm the baseline and reporting routes

Before or at launch, preserve the approved use statement, current vendor or feature version, integration and configuration summary, named operational and executive owners, training status, initial evidence reviewed, and initial monitoring choices. Confirm that staff know how to pause, bypass, or escalate the workflow if a serious concern appears.

This stage is also the right time to test the issue route. A team should not discover during an urgent event that users do not know who receives a concern or that incident, privacy, security, clinical, and vendor-management teams have incompatible records.

Days 31–60: compare actual use with the approved design

Review whether the workflow is being used as intended, whether unanticipated workarounds have developed, and whether selected signals are useful enough to support a decision. Ask the people closest to the work what they cannot see, what is difficult to explain, and what exceptions are recurring.

If a metric does not help an accountable owner make a decision, adjust it. If an important risk or limitation cannot yet be measured, keep that limitation in the record and determine whether an alternate control, more evidence, or a narrower use scope is needed.

Days 61–90: make the first governance decision

At the 90-day review, do not treat a lack of reported problems as a blanket endorsement. Review the intended use, evidence, selected signals, changes, feedback, open issues, completed actions, and residual uncertainty. Record one of four outcomes:

| Decision | What it means | |---|---| | Continue as defined | The organisation has reviewed the available evidence for the defined use and retains the existing monitoring plan. | | Continue with conditions | The workflow may continue only while named actions, controls, or additional evidence are completed by accountable owners. | | Modify and re-review | A material change to data, configuration, workflow, users, or use statement requires a defined review before routine continuation. | | Pause, bypass, or retire | The system or component requires a temporary or permanent change because its outcomes, risks, or conditions are inconsistent with the approved use. |

These are governance decisions, not certifications. The decision record should state what evidence was considered, what was not known, who owned follow-up, and when the next review will occur.

Define escalation and stop conditions before they are needed

Escalation works when the team does not have to invent it in the moment. A plan should distinguish routine operational issues from events that require clinical, privacy, security, compliance, executive, legal, or vendor-management involvement.

Examples of possible triggers include a material vendor release, altered data source, integration failure, concerning reliability pattern, unexpected output or workflow behaviour, serious user feedback, suspected privacy or security issue, use outside the approved scope, or a threshold set by the organisation for that specific workflow. These are examples—not a universal set of reporting thresholds.

NIST’s Manage guidance calls for post-deployment monitoring plans that include input from users and relevant AI actors, appeal and override, decommissioning, incident response, recovery, and change management. It also describes the need for mechanisms and assigned responsibilities to supersede, disengage, or deactivate AI systems whose outcomes are inconsistent with intended use.

For a healthcare organisation, a stop or bypass plan should be operationally specific: who can act, what temporary workflow replaces the capability, how records or work queues are reconciled, how affected staff are informed, what evidence is preserved, and who decides whether and how the system returns to use.

Keep monitoring connected to procurement and governance

Monitoring should not be a spreadsheet built after a contract is signed. It should reuse the evidence, commitments, data boundaries, intended use, and open questions that were recorded during evaluation.

Start with the healthcare AI procurement evidence register and carry forward the fields that matter after launch: version, evidence source, known limitations, data and integration boundaries, human-review expectations, open conditions, owners, and next review triggers.

For AI or predictive decision-support interventions within certified health IT, the ASTP/ONC HTI-1 Decision Support Interventions fact sheet describes a specific certification-program context for decision support interventions and predictive models. It should not be represented as a universal approval of a local AI deployment. It can, however, help healthcare leaders ask more precise questions about intended use, transparency information, risks, and the evidence available for their own review.

The healthcare AI governance committee charter outlines a practical place to receive these monitoring findings, decide on conditions, and route issues to the people who hold specialist authority.

A practical monitoring-plan starter template

A first version can be a controlled register, not a new software platform. Include at least:

• system, feature, vendor, configuration, and approved intended use;
• named operational, clinical, technical, privacy, security, and executive owners as applicable;
• selected signals, definitions, sources, limitations, thresholds, and review cadence;
• feedback, incident, override, and appeal routes;
• change triggers, decision rights, escalation paths, and bypass or deactivation procedures;
• evidence reviewed, open conditions, decisions, dates, and next-review triggers; and
• a record of what has not been measured, why, and what compensating action is in place.

A plan is credible when it helps an organisation identify what is changing, decide who should act, and retain evidence of what happened. It does not need to make unsupported promises about safety, compliance, or performance.

Build monitoring that fits the workflow

Eunoia Consulting Co. helps healthcare organisations translate AI governance commitments into operating controls for procurement, implementation, change, monitoring, and escalation. To discuss a monitoring plan for a defined healthcare workflow, explore Eunoia’s AI governance advisory services or contact the team. This is advisory support for internal decision readiness, not legal, clinical, privacy, security, or regulatory advice.

Sources

• NIST AI Risk Management Framework Core — Measure and Manage
• NIST AI RMF Playbook — Measure
• NIST AI RMF Playbook — Manage
• ASTP/ONC — HTI-1 Decision Support Interventions and Predictive Models